Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Feb 15.
Published in final edited form as: Circ Res. 2013 Jan 8;112(4):640–650. doi: 10.1161/CIRCRESAHA.113.300897

Dihydropyridine Ca2+ Channel Blockers Increase Cytosolic [Ca2+] by Activating Ca2+-sensing Receptors in Pulmonary Arterial Smooth Muscle Cells

Aya Yamamura 2, Hisao Yamamura 3, Qiang Guo 1, Adriana M Zimnicka 1, Jun Wan 1, Eun A Ko 1, Kimberly A Smith 1, Nicole M Pohl 1, Shanshan Song 1, Amy Zeifman 1, Ayako Makino 1, Jason XJ Yuan 1
PMCID: PMC3642037  NIHMSID: NIHMS444311  PMID: 23300272

Abstract

Rationale

An increase in cytosolic free Ca2+ concentration ([Ca2+]cyt) in pulmonary arterial smooth muscle cells (PASMC) is a major trigger for pulmonary vasoconstriction and an important stimulus for PASMC proliferation and pulmonary vascular remodeling. The dihydropyridine Ca2+ channel blockers, such as nifedipine, have been used for treatment of idiopathic pulmonary arterial hypertension (IPAH).

Objective

Our previous study demonstrated that the Ca2+-sensing receptor (CaSR) was upregulated and the extracellular Ca2+-induced increase in [Ca2+]cyt was enhanced in PASMC from patients with IPAH and animals with experimental pulmonary hypertension. Here, we report that the dihydropyridines (e.g., nifedipine) increase [Ca2+]cyt by activating CaSR in PASMC from IPAH patients (in which CaSR is upregulated), but not in normal PASMC.

Methods and Results

The nifedipine-mediated increase in [Ca2+]cyt in IPAH-PASMC was concentration dependent with an EC50 of 0.20 µM. Knockdown of CaSR with siRNA in IPAH-PASMC significantly inhibited the nifedipine-induced increase in [Ca2+]cyt, whereas overexpression of CaSR in normal PASMC conferred the nifedipine-induced rise in [Ca2+]cyt. Other dihydropyridines, nicardipine and Bay K8644, had similar augmenting effects on the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC; however, the non-dihydropyridine blockers, such as diltiazem and verapamil, had no effect on the CaSR-mediated rise in [Ca2+]cyt.

Conclusions

The dihydropyridine derivatives increase [Ca2+]cyt by potentiating the activity of CaSR in PASMC independently of their blocking (or activating) effect on Ca2+ channels; therefore, it is possible that use the dihydropyridine Ca2+ channel blockers (e.g., nifedipine) to treat IPAH patients with upregulated CaSR in PASMC may exacerbate pulmonary hypertension.

Keywords: Calcium channel blocker, calcium-sensing receptor, nifedipine, nicardipine, pulmonary hypertension, smooth muscle cell

INTRODUCTION

Pulmonary vascular remodeling and sustained pulmonary vasoconstriction greatly contribute to the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with pulmonary arterial hypertension (PAH). An increase in cytosolic free Ca2+ concentration ([Ca2+]cyt) in pulmonary arterial smooth muscle cells (PASMC) is a major trigger for pulmonary vasoconstriction (by triggering PASMC contraction) and a critical stimulus for pulmonary vascular medial hypertrophy (by stimulating PASMC migration and proliferation). Intracellular Ca2+, or cytosolic free Ca2+, is thus an important signaling element that mediates PASMC contraction, migration and proliferation upon membrane depolarization and/or activation of membrane receptors by vasoactive and mitogenic factors.

By selectively blocking voltage-dependent Ca2+ channels (VDCC) in vascular smooth muscle cells, the dihydropyridine Ca2+ channel blockers (e.g., nifedipine, nicardipine) have been used to treat patients with systemic1, 2 and pulmonary3, 4 hypertension. In 15–20% of patients with idiopathic pulmonary arterial hypertension (IPAH), acute administration of nifedipine or other vasodilators could significantly reduce pulmonary arterial pressure. In these clinically considered as the vasoreactive patients (or responders)3–8, the high-dose of Ca2+ channel blockers (e.g., nifedipine) also has long-term therapeutic and beneficial effects determined by hemodynamics, exercise capacity and survival rate.3, 4, 9 It is unclear, however, why the classical dihydropyridine Ca2+ channel blockers do not work well in the majority of IPAH patients and even cause deterioration of the disease.

The Ca2+-sensing receptor (CaSR) is a G protein-coupled receptor (GPCR) in the plasma membrane that can be activated by extracellular Ca2+ (and Mg2+), polyamines (e.g., spermine), amino acids and neomycin.10–13 Activation of CaSR sets into motion a complex series of intracellular Ca2+ signaling events that may be involved in stimulating PASMC contraction, proliferation and migration.14, 15 Like some GPCRs coupled to Gq (e.g., endothelin receptors), CaSR activation increases the synthesis of inositol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG) via phospholipase C (PLC). IP3 binds to the IP3 receptor (IP3R) on the sarcoplasmic reticulum (SR) membrane and releases Ca2+ from the SR to the cytosol. Depletion of Ca2+ from the SR induces Ca2+ entry through store-operated Ca2+ channels (SOC), also referred to as store-operated Ca2+ entry (SOCE) or capacitative Ca2+ entry. DAG directly activates receptor-operated Ca2+ channels (ROC) in the plasma membrane; the Ca2+ entry through ROC is termed receptor-operated Ca2+ entry (ROCE). In addition to increasing [Ca2+]cyt via ROCE and SOCE, the extracellular Ca2+-induced activation of CaSR also activates other signal transduction pathways (e.g., Akt/mTOR and MAPK/ERK) to induce cell proliferation.16–18

Our recent study14 indicated that the extracellular Ca2+-induced increase in [Ca2+]cyt by activation of CaSR was enhanced and the CaSR protein expression was upregulated in IPAH-PASMC compared to normal PASMC. Inhibition of CaSR by siRNA in IPAH-PASMC significantly attenuated the extracellular Ca2+-induced rise in [Ca2+]cyt and markedly inhibited IPAH-PASMC proliferation. Similarly, the extracellular Ca2+-induced increase in [Ca2+]cyt was enhanced and the mRNA and protein expression of CaSR was upregulated in PASMC isolated from rats with monocrotaline (MCT)-induced PH (MCT-PH) compared to PASMC from control rats. Blockade of CaSR by the calcilytic NPS-2143 inhibited the development of MCT-PH. These observations suggest that upregulated expression and enhanced function of CaSR in PASMC are involved in the development of sustained pulmonary vasoconstriction and pulmonary vascular remodeling in patients with IPAH and animals with experimental pulmonary hypertension.

In this study, we examined and compared the effects of dihydropyridine Ca2+ channel blockers on the CaSR-mediated increase in [Ca2+]cyt in normal PASMC (with low expression level of CaSR) and IPAH-PASMC (with upregulated expression level of CaSR). The data from this study indicate that the dihydropyridine Ca2+ channel blockers (e.g., nifedipine, nicardipine), although effectively block VDCC in PASMC, significantly enhance the activity of CaSR that is upregulated in PASMC from patients with IPAH and animals with experimental pulmonary hypertension. These observations provide a novel explanation for why the therapeutic effect of nifedipine and other dihydropyridine Ca2+ blockers is compromised in many IPAH patients. The data from this study also imply that caution should be exercised when the use of nifedipine and nicardipine is considered for treatment of IPAH patients with upregulated CaSR in PASMC and the gain-of-function mutations in the CaSR gene.

MATERIALS AND METHODS

Cell preparation and culture

Explanted peripheral lung tissues of normal control subjects (two unsuitable organ donors and two COPD patients without pulmonary hypertension) and patients with IPAH (three patients diagnosed on the basis of NIH IPAH Registry with an averaged mean PAP of 56±5 mmHg who were non-responders in response to inhalation of nitric oxide or acute intravenous infusion of prostacyclin and Ca2+ channel blocker) were used to isolate human PASMC from small pulmonary arteries (with an outer diameter of 300–500 µm).19, 20 PASMC were also isolated from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension (CTEPH, four patients with an averaged mean PAP of 39±5 mmHg).21 Use of human lung tissues and cells was approved by the UIC Institutional Review Board. Human PASMC (passages 5 to 10) cultured in Medium 199 supplemented with 10% fetal bovine serum (Invitrogen, Grand Island, NY), 100 U/ml penicillin plus 100 µg/ml streptomycin, 50 µg/ml D-valine (Sigma-Aldrich, St. Louis, MO), and 20 µg/ml endothelial cell growth supplement (BD Biosciences, Franklin Lakes, NJ) at 37°C were used for the experiments.

[Ca2+]cyt measurement

[Ca2+]cyt in PASMC was analyzed using a ratiometric method described previously.22 Briefly, PASMC cultured on 25-mm cover slips (Fisher Scientific, Pittsburgh, PA) were incubated in HEPES-buffered solution containing 4 µM fura-2 acetoxymethyl ester (fura-2/AM; Invitrogen/Molecular Probes, Eugene, OR) for 60 min at room temperature (25°C). The fura-2-loaded cells were placed in a recording chamber on the stage of an invert fluorescent microscope (Eclipse Ti-E; Nikon, Tokyo, Japan) equipped with an objective lens (S Plan Fluor 20×/0.45 ELWD; Nikon), an EM-CCD camera (Evolve; Photometrics, Tucson, AZ), and the NIS Elements 3.2 software (Nikon). [Ca2+]cyt within a region of interest (5×5 µm) was measured as the ratio of fluorescence intensities (F340/F380) of fura-2 at the rate of every 2 seconds. The HEPES-buffered bath solution had an ionic composition of 137 mM NaCl, 5.9 mM KCl, 2.2 mM CaCl2, 1.2 mM MgCl2, 14 mM glucose, and 10 mM HEPES. The pH was adjusted to 7.4 with 10 N NaOH. The Ca2+-free bath solution was prepared by adding 1 mM EGTA and replacing CaCl2 with equimolar MgCl2. Cells in the recording chamber were continuously superfused with HEPES-buffered solution at a flow rate of 2 ml/min. All experiments were carried out at 32°C.

Transfection of cDNA and small interfering RNA (siRNA)

Cultured PASMC were transiently transfected by electroporation with 2 µg of human CaSR cDNA (constructed into pcDNA3.1(+); Invitrogen), 50 nM of control siRNA or scrambled siRNA (sc-37007; Santa Cruz Biotechnology), or siRNA for CaSR (s2440; Applied Biosystems/Ambion, Austin, TX) using an Amaxa Basic Nucleofector kit (Lonza). Experiments using CaSR-overexpressed and siRNA-transfected cells were performed 48 h after electroporation.

Drugs

All pharmacological reagents were obtained from Sigma-Aldrich. Dihydropyridine compounds (nifedipine, nicardipine, and Bay K8644) were dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. Diltiazem and verapamil were dissolved in distilled water to make a stock solution of 10 mM. Aliquots of the stock solutions were then dissolved into the HEPES-buffered bath solution at various concentrations on the day when the experiments were performed.

MCT-induced pulmonary hypertension

Adult male Sprague-Dawley rats (190–200g in body weight; Charles River Laboratories) were given a single subcutaneous injection of vehicle (DMSO) or 60 mg/kg MCT (Sigma-Aldrich) to induce pulmonary hypertension. For nifedipine treatment, rats were given intraperitoneal (i.p.) injections of nifedipine (1 mg/kg, once a day for 2 weeks) either 2 or 4 weeks after MCT injection. For hemodynamic measurements, the animals were anesthetized with an i.p. injection of ketamine (100mg/kg) and xylazine (26mg/kg). Right ventricular pressure (RVP) was determined with a pressure transducer catheter (SPF869, Millar Instruments, Houston, TX) inserted through the right jugular vein and MPVS Ultra (Millar Instruments) data acquisition system. Data was then recorded and analyzed with AD Instruments Lab Chart Pro7.0 software.

Statistical analysis

Pooled data are shown as the mean±S.E. The statistical significance between two groups was determined by Student’s t-test. The statistical significance among groups was determined by Scheffé’s test after one-way analysis of variance. Significant difference is expressed in the figures or figure legends as *P<0.05 or **P<0.01.

RESULTS

To test the effects of dihydropyridines on [Ca2+]cyt, we first conducted patch clamp experiments to confirm that nifedipine inhibits, and Bay K8644 activates, VDCC in PASMC. As shown in Figure 1, extracellular application of 1 µM nifedipine significantly decreased whole-cell Ca2+ currents in PASMC, elicited by depolarizing the cells from a holding potential of −70 mV to +10 mV (Fig. 1A), whereas Bay K8644 (10 µM) significantly enhanced the currents (Fig. 1B). Consistent with its inhibitory effect on L-type Ca2+ channels, acute application of nifedipine (1 µM) also significantly and reversibly inhibited pulmonary vasoconstriction induced by 80 mM K+-mediated membrane depolarization in isolated pulmonary arterial rings (Fig. 1C). These data confirm that nifedipine is a blocker of VDCC, whereas Bay K8644 is an activator of VDCC in PASMC.

Figure 1. Inhibitory effect of nifedipine on VDCC in normal PASMC and augmenting effect of nifedipine on CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC.

Figure 1

A and B: Representative whole-cell Ca2+ currents (upper panels), elicited by depolarizing the cells from a holding potential of −70 mV to a test potential of +10 mV (300 ms), in normal PASMC before (Cont) and during extracellular application of 1 µM nifedipine (Nif, A) or 1 µM Bay K8644 (Bay K, B). Summarized data (means±SE, lower panels) showing current density in normal PASMC before (Cont) and during application of Nif or Bay K. ** P<0.01 and *P<0.05 vs. Cont. C: Representative record of isometric tension (upper panel) in an isolated pulmonary arterial ring from mouse before, during and after superfusion of 80 mM K+ (80K)-containing solution in the absence and presence of 1 µm Nif. Summarized data (means±SE, lower panel) showing 80K-mediated active tension before (80K), during (80K+Nif) and after (80K) treatment with 1 µM Nif. *P<0.05 vs. 80K. D and E: Representative traces (D) and pseudocolor images (E) showing changes in [Ca2+]cyt in normal (blue), IPAH (red) and CTEPH (dark green) PASMC bathed in Ca2+-free solution (0Ca) before, during and after restoration of extracellular Ca2+ to 2.2 mM (2.2Ca, solid horizontal bars) in the absence or presence of 1 µM nifedipine (Nif). F: Summarized data (means±SE) showing the amplitude of the 2.2Ca-induced transient (left panel) and plateau (right panel) phases of the increase in [Ca2+]cyt before (Cont) and after treatment with 1 µM Nif (Nif) in normal (Nor), IPAH and CTEPH PASMC. ** P<0.01 vs. Nor and CTEPH PASMC.

Nifedipine enhances CaSR-mediated increases in [Ca2+]cyt in PASMC from IPAH patients

To elucidate the effects of dihydropyridines on CaSR-mediated increases in [Ca2+]cyt, we first superfused PASMC with Ca2+-free bath solution (0Ca) for 10 min and then with 2.2 mM-containing bath solution (2.2Ca) for 10–20 min to induce a rise in [Ca2+]cyt as a result of the extracellular Ca2+-mediated activation of CaSR. Then, we applied the dihydropyridines, nifedipine, nicardipine and Bay K8644 to cells prior to the extracellular Ca2+-induced rise in [Ca2+]cyt and compared the effects on the CaSR-mediated increases in [Ca2+]cyt in PASMC isolated from normal subjects (Normal), patients with IPAH (IPAH) and patients with CTEPH (CTEPH).

In normal PASMC perfused with Ca2+-free solution (0 mM Ca2+ and 1 mM EGTA) for 10 min, restoration of extracellular Ca2+ (to 2.2 mM) had little effect on [Ca2+]cyt (Fig. 1D, left panel, and E, upper panels). In IPAH-PASMC, however, restoration of extracellular Ca2+ induced a transient increase in [Ca2+]cyt (Fig. 1D, middle panel, and E, middle panels). In CTEPH-PASMC, restoration of external Ca2+ had negligible effect on [Ca2+]cyt (Fig. 1D, right panel, and E, lower panels). In the absence of nifedipine, the extracellular Ca2+-induced increase in [Ca2+]cyt via CaSR activation is composed of a large transient phase and a small plateau phase in IPAH-PASMC (Fig. 1D).

Extracellular application of nifedipine (1 µM), a dihydropyridine VDCC channel blocker (Fig. 1A), however, significantly enhanced the extracellular Ca2+-mediated increase in [Ca2+]cyt in IPAH-PASMC, but not in normal PASMC and CTEPH-PASMC (Fig. 1D–F). The exclusive enhancement of the extracellular Ca2+-induced increase in [Ca2+]cyt by nifedipine in IPAH-PASMC was potentially due to the upregulation of CaSR protein expression in these cells compared to PASMC from normal subjects and CTEPH patients.14 Extracellular application of vehicle (0.1% DMSO) did not affect the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC (data not shown). These data indicate that nifedipine significantly enhances the extracellular Ca2+-mediated increase in [Ca2+]cyt in IPAH PASMC where protein expression of CaSR is upregulated in comparison to normal PASMC. In the next set of experiments, we examined whether nifedipine directly affected the resting [Ca2+]cyt in PASMC.

Nifedipine directly increases [Ca2+]cyt in PASMC with upregulated CaSR expression

In normal PASMC and CTEPH-PASMC, extracellular application of 1 µM nifedipine had no effect on the resting [Ca2+]cyt in the absence or presence of extracellular Ca2+, whereas in IPAH-PASMC with upregulated CaSR, nifedipine significantly increased the resting [Ca2+]cyt (Fig. 2A and B). The resting [Ca2+]cyt in IPAH-PASMC was dramatically increased by nifedipine in the presence of extracellular Ca2+ (Fig. 2A, middle panels, and B–C). Even in the absence of extracellular Ca2+, nifedipine caused a slight, but statistically significant, increase in [Ca2+]cyt in IPAH-PASMC (Fig. 2A, middle panels, and B–C). The nifedipine-mediated increase in the resting [Ca2+]cyt in IPAH-PASMC was dose dependent (at the range of 0.01 µM to 10 µM) with an EC50 of 0.21 µM and a Hill coefficient of 1.29 (Fig. 3).

Figure 2. Nifedipine increases the resting [Ca2+]cyt in IPAH-PASMC with upregulated CaSR.

Figure 2

A and B: Representative traces (A) and pseudocolor images (B) showing changes in [Ca2+]cyt in normal (blue), IPAH (red) and CTEPH (dark green) PASMC before (Cont), during (Nif) and after application of 1 µM nifedipine (Nif) in the absence (0Ca, left panels) or presence (2.2Ca) of extracellular Ca2+. C: Summarized data (means±SE) showing the amplitude of Nif-induced transient and plateau phases of increases in [Ca2+]cyt in normal, IPAH and CTEPH PASMC. ** P<0.01 vs. normal and CTEPH PASMC.

Figure 3. Nifedipine increases the resting [Ca2+]cyt in IPAH-PASMC in a dose-dependent manner.

Figure 3

A: A representative trace showing changes in [Ca2+]cyt before, during and after application of nifedipine at concentrations of 0.01 to 10 µM in IPAH PASMC. Inset: the structural formula of nifedipine. B: The dose-response curve of nifedipine-mediated increases in [Ca2+]cyt in IPAH-PASMC (data are expressed as means±SE). The EC50 value for the effect of nifedipine on the resting [Ca2+]cyt in IPAH-PASMC is calculated to be 0.21 µM (inset).

These data indicate that nifedipine not only enhances the extracellular Ca2+-induced increase in [Ca2+]cyt but also directly increases the resting [Ca2+]cyt in IPAH-PASMC with upregulated CaSR. We speculate that nifedipine may directly activate CaSR to induce the increase in [Ca2+]cyt and/or synergistically activate CaSR with the extracellular Ca2+ to elicit the rise in [Ca2+]cyt in IPAH-PASMC.

Negligible effect of non-dihydropyridine Ca2+ channel blockers on CaSR-mediated increase in [Ca2+]cyt

In addition to nifedipine, we examined whether other dihydropyridine derivatives affect CaSR-mediated rise in [Ca2+]cyt. In IPAH-PASMC, acute application of 1 µM nicardipine, a dihydropyridine Ca2+ channel blocker, significantly enhanced the extracellular Ca2+-induced increase in [Ca2+]cyt (Fig. 4A). Surprisingly, the dihydropyridine Ca2+ channel activator, Bay K8644 (1 µM) also augmented the extracellular Ca2+-induced rise in [Ca2+]cyt in IPAH-PASMC (Fig. 4B). Next, we examined the effect of non-dihydropyridine Ca2+ channel blockers on the CaSR-mediated increase in [Ca2+]cyt. In IPAH-PASMC, acute application of 10 µM diltiazem, a benzothiazepine Ca2+ channel blocker (Fig. 4C), or 10 µM verapamil, a phenylalkylamine Ca2+ channel blocker (Fig. 4D), had no effect on the extracellular Ca2+-induced rises in [Ca2+]cyt. When IPAH-PASMC were superfused with Ca2+-containing solution, both nicardipine (Fig. 4E) and Bay K8644 (Fig. 4F) significantly increased the resting [Ca2+]cyt (Fig. 4I); however, neither diltiazem (Fig. 4H) nor verapamil (Fig. 4H) increased the resting [Ca2+]cyt (Fig. 4I). These data indicate that a) the augmenting effect of the dihydropyridine derivatives on CaSR-mediated increase in [Ca2+]cyt is independent of their effects (inhibition or activation) on VDCC in PASMC; and b) the augmenting effect on the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC is selective to the dihydropyridine derivatives.

Figure 4. Divergent effects of dihydropyridines and non-dihydropyridine Ca2+ channel blockers on CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC.

Figure 4

A–D: Representative traces (upper panels) showing the changes in [Ca2+]cyt in IPAH-PASMC bathed in Ca2+-free solution (0Ca) before, during, and after addition of 2.2 mM extracellular Ca2+ (2.2Ca, solid horizontal bars) in the absence or presence of 1 µM nicardipine (A; a dihydropyridine Ca2+ channel blocker), 1 µM Bay K8644 (B; a dihydropyridine Ca2+ channel activator), 10 µM diltiazem (C; a benzothiazepine Ca2+ channel blocker), or 10 µM verapamil (D; a phenylalkylamine Ca2+ channel blocker). Summarized data (means±SE, lower panels) showing the amplitude of the transient and plateau phases of the extracellular Ca2+-induced rise in [Ca2+]cyt in IPAH-PASMC with or without (Control) pretreatment of nicardipine, Bay K8644, diltiazem or verapamil. **P<0.01 vs. Control. The structural formula of nicardipine, Bay K8644, diltizaem and verapamil are shown on the top of each panel. E–H: Representative traces showing the changes in the resting [Ca2+]cyt before, during, and after application of nicardipine (1 µM, E), Bay K8644 (1 µM, F), diltiazem (10 µM, G) or verapamil (10 µM, H) in IPAH-PASMC. I: Summarized data (means±SE) showing the amplitude of increases in the resting [Ca2+]cyt induced by nicardipine, Bay K8644, diltiazem or verapamil in IPAH-PASMC. **P<0.01 vs. diltiazem and verapamil.

CaSR is necessary and sufficient to mediate the nifedipine-mediated increase in [Ca2+]cyt in PASMC

To obtain direct evidence for the involvement of CaSR in the nifedipine-induced increase in [Ca2+]cyt, we examined the nifedipine effect in IPAH-PASMC treated with the CaSR-specific siRNA and in normal PASMC transfected with CaSR. As shown in Figure 5, transfection of the CaSR-siRNA into IPAH-PASMC decreased CaSR protein expression level (Fig. 5A) and significantly inhibited the nifedipine-mediated increase in the resting [Ca2+]cyt in comparison to control cells transfected with scrambled siRNA (control siRNA) (Fig. 5B). The averaged data and histograms of the nifedipine-mediated rise in the resting [Ca2+]cyt both show that upregulated CaSR is necessary for the nifedipine-mediated increase in [Ca2+]cyt (Fig. 5C and D). Additionally, treatment of IPAH-PASMC with the allosteric CaSR antagoinist, NPS-2143, significantly attenuated the nifedipine-mediated rise in [Ca2+]cyt (Online Fig. I). In normal PASMC, overexpression of CaSR markedly enhanced the protein level of CaSR (Fig. 6A) and significantly enhanced the nifedipine-mediated increase in [Ca2+]cyt in comparison to normal cells transiently transfected with an empty vector (Fig. 6B–D). These data indicate that CaSR is necessary and sufficient for the nifedipine-mediated increases in [Ca2+]cyt in PASMC.

Figure 5. CaSR is necessary for the dihydropyridine-mediated increase in [Ca2+]cyt in IPAH-PASMC.

Figure 5

A: Western blot analysis of CaSR in IPAH-PASMC treated with control siRNA (Control) and CaSR siRNA in different concentration (10, 20 or 30 pmol). β-tubulin is used as a control. B: Representative traces showing changes in the resting [Ca2+]cyt before, during, and after application of 1 µM nifedipine (Nif) in IPAH-PASMC treated with control siRNA or CaSR-siRNA. C: Summarized data (means±SE) showing the amplitude of Nif-induced increases in [Ca2+]cyt in IPAH-PASMC treated with control siRNA (Cont siRNA) or CaSR-siRNA. **P<0.01 vs. Cont. D: Amplitude distributions of the Nif-induced rise in [Ca2+]cyt in IPAH-PASMC treated with Cont siRNA (upper panel) or CaSR-siRNA (lower panel).

Figure 6. CaSR is sufficient for the dihydropyridine-mediated increase in [Ca2+]cyt in normal PASMC.

Figure 6

A: Western blot analysis of CaSR in normal PASMC transiently transfected with an empty vector (Vector) and the human CaSR gene (CaSR). β-tubulin is used as a control. B: Representative traces showing changes in the resting [Ca2+]cyt before, during, and after application of 1 µM nifedipine (Nif) in normal PASMC transfected with Vector or CaSR. C: Summarized data (means±SE) showing the amplitude of Nif-induced increases in [Ca2+]cyt in normal PASMC transfected with Vector or CaSR. **P<0.01 vs. Vector. D: Amplitude distributions of the Nif-induced increase in [Ca2+]cyt in normal transfected with Vector (upper panel) or CaSR (lower panel).

Nifedipine further increases RVSP in rats with established pulmonary hypertension

In addition to the upregulation in PASMC from IPAH patients, we found that the mRNA and protein expression of CaSR was also upregulated in PASMC, pulmonary arteries and lung tissues from animals with monocrotaline (MCT)-mediated pulmonary hypertension (MCT-PH)14 (Fig. 7A and B). In rats with established MCT-PH (2 weeks after initial injection of MCT), intraperitoneal injection of nifedipine (1 mg/kg, once a day for 2 weeks) further enhanced the right ventricular systolic pressure (RVSP) (Fig. 7C and D). RVSP in MCT-PH rats intraperitoneally injected with nifedipine was significantly higher (P=0.011) than in MCT-PH rats injected with vehicle (Fig. 7D). The enhanced RVSP was accompanied by further right ventricular hypertrophy determined by the Fulton index, the ratio of RV/(LV+S) (Fig. 7E). In rats with more severe MCT-PH (4 weeks after initial injection of MCT), however, the nifedipine-mediated enhancement of RVSP (Fig. 7F and G) was not associated with a further increase in RV hypertrophy (Fig. 7H). These data indicate that, in established pulmonary hypertension induced by MCT, nifedipine actually exacerbates the pulmonary vascular hemodynamics (i.e., further increases RVSP), potentially by stimulating CaSR in PASMC. The blockade effect of nifedipine on VDCC is probably compromised by the activating effect on CaSR that is upregulated in PASMC of animals with established pulmonary hypertension.

Figure 7. Intraperitoneal injection of nifedipine in animals with established pulmonary hypertension further increases right ventricular systolic pressure and right ventricular hypertrophy.

Figure 7

A and B. Western blot analysis (A) and summarized data (mean±SE, B) of CaSR in whole lung tissues isolated from control and MCT-PH animals. β-actin is used as a control. C and D. Representative record of right ventricular pressure (RVP, C) and summarized data (mean±SE) showing the peach value of right ventricular systolic pressure (RVSP, D) in normal control rats (Cont, n=6) and MCT-injected rats (MCT, n=6) that are treated with vehicle or nifedipine (+Nif, 1 mg/kg/day for 2 weeks) 2 weeks after the MCT injection. E. Averaged Fulton index [RV/(LV+S) ratio, mean±SE] showing that RV hypertrophy is further increased in MCT-rats treated with nifedipine. F and G. Representative record of right ventricular pressure (RVP, F) and summarized data (mean±SE) showing the peach value of RVSP (G) in normal control rats (Cont, n=6) and MCT-injected rats (MCT, n=6) that are treated with vehicle or nifedipine (+Nif, 1 mg/kg/day for 4 weeks) 4 weeks after the MCT injection. H. Averaged Fulton index [RV/(LV+S) ratio, mean±SE] showing that RV hypertrophy is not further increased in MCT-rats treated with nifedipine 4 weeks after MCT injection.

In animals exposed to chronic hypoxia, many investigators have shown that nifedipine (and other dihydropyridine or non-dihydropyridine Ca2+ channel blockers) prevents (or significantly attenuates) the development of pulmonary hypertension. Chronic hypoxia has been demonstrated to downregulate voltage-gated K+ (Kv) channels causing membrane depolarization that subsequently opens VDCC and increases [Ca2+]cyt in PASMC.23–26 By blocking VDCC, nifedipine would inhibit Ca2+ influx through VDCC and prevent the development of sustained pulmonary vasoconstriction and pulmonary vascular medial hypertrophy. Our preliminary data showed that CaSR was upregulated in PASMC from animals with both MCT-PH and HPH14, while Zhang et al. demonstrated that activation of mitochondrial H2O2-sensitized CaSR by extracellular Ca2+ is involved in hypoxic pulmonary vasoconstriction.15 It is thus unclear why nifedipine only enhanced the development of pulmonary hypertension in MCT-PH rats, but not in HPH animals.27–29

DISCUSSION

The major findings of this study are that dihydropyridine derivatives, regardless of their blocking (nifedipine, nicardipine) or activating (Bay K8644) effect on VDCC, enhanced the extracellular Ca2+-induced rise in [Ca2+]cyt and increased the resting [Ca2+]cyt in PASMC from IPAH patients and MCT-PH rats in which CaSR was upregulated. Knockdown of CaSR by siRNA in IPAH-PASMC significantly attenuated the nifedipine-induced increase in [Ca2+]cyt, whereas overexpression of CaSR by transiently transfecting the human CaSR gene into normal PASMC augmented the nifedipine-mediated rise in [Ca2+]cyt. In contrast, non-dihydropyridine Ca2+ blockers, e.g., diltiazem (a benzothiazepine VDCC blocker) and verapamil (a phenylalkylamine VDCC blocker), had no effect on the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC.

CaSR (also known as GPCR2A) is a G protein-coupled receptor (GPCR) that can be activated by polyvalent cations (Ca2+, Mg2+, and Gd3+), amino acids (phenylalanine and glutamate), endogenous polyamines (spermine and spermidine), polypeptides (amyloid-β peptide), and aminoglycoside antibiotics (neomycin), as well as synthetic pharmacological compounds (e.g., R-568 and cinacalcet).16–18 CaSR is expressed in parathyroid gland, kidney, bone, gastrointestinal tract, skin, brain, and heart.16, 30, 31 CaSR is also expressed in vascular smooth muscle cells32–38 and endothelial cells.39, 40 Activation of CaSR33, 34, 38 is involved in the regulation of myogenic tone, peripheral vascular resistance, arterial blood pressure, and hypoxic pulmonary vasoconstriction.1, 2, 15, 36 CaSR in vascular smooth muscle cells has been shown to contribute to regulating cell proliferation and apoptosis through the mitogen-activated protein kinase (MAPK) and the phospholipase C (PLC) cascades.35, 37, 41

Recently, we found that CaSR was significantly upregulated in PASMC from IPAH patients in comparison to normal controls. The upregulated CaSR protein expression was associated with a markedly enhanced Ca2+-induced increase in [Ca2+]cyt in IPAH-PASMC.14 Since CaSR was upregulated and extracellular Ca2+-mediated increase in [Ca2+]cyt was enhanced in PASMC from IPAH patients and in PASMC from animals with experimental pulmonary hypertension, our previous data showed that intraperitoneal injection of the calcilytic NPS-2143 indeed significantly inhibited the development of pulmonary hypertension in animals injected with MCT.14

As shown in this study (Fig. 1), the nifedipine-induced increase in [Ca2+]cyt only occurred in IPAH-PASMC where CaSR was upregulated and in CaSR-transfected normal PASMC where CaSR was overexpressed. These data suggested that the dihydropyridine compounds (nifedipine, nicardipine and Bay K8644) can directly activate CaSR. As a GPCR, activated CaSR signals through inositol-1,4,5-trisphosphate (IP3) and diacyglycerol (DAG) to increase [Ca2+]cyt. IP3 increases [Ca2+]cyt by stimulating Ca2+ release from the SR to the cytosol via IP3 receptors on the SR membrane, while DAG increases [Ca2+]cyt by augmenting Ca2+ influx through receptor-operated Ca2+ channels (ROC) on the plasma membrane. In the absence of extracellular Ca2+, the nifedipine-induced increase in [Ca2+]cyt in IPAH PASMC was much smaller than we expected (Fig. 2), in comparison to other GPCR agonists. This phenomenon is, however, very similar to the response to spermine that directly activates CaSR.33, 40 The marked decline in the nifedipine-induced increase in [Ca2+]cyt in IPAH-PASMC superfused with Ca2+-free solution indicates that a) Ca2+ influx is the predominant pathway to increase [Ca2+]cyt upon activation of CaSR (by nifedipine or spermine), and b) CaSR is synergistically activated by extracellular Ca2+ and nifedipine (or spermine) to trigger the increase in [Ca2+]cyt (through Ca2+ release and influx). It has been demonstrated that CaSR is functionally coupled to Ca2+ channels on the plasma membrane (e.g., transient receptor potential (TRP) channels, TRPC1/C3/C6, TRPV5, and TRPM4/M5) to mediate Ca2+ influx.33, 42–46

Dihydropyridine Ca2+ channel blockers (e.g., nifedipine and nicardipine) are selective blockers of VDCC which have been widely used for the treatment of cardiovascular diseases, such as hypertension, angina, and arrhythmia.47, 48 Conventional Ca2+ channel blockers (i.e., nifedipine and diltiazem) that selectively block VDCC in PASMC have been used to effectively treat 15–20% of IPAH patients who are considered as pulmonary vasoreactive responders.3, 4, 49 It is however unknown why conventional Ca2+ channel blockers (i.e., VDCC blockers) are not therapeutically effective for a majority of patients with pulmonary arterial hypertension, especially the patients with severe pulmonary hypertension.3, 4, 49 In future studies, it would be very interesting to investigate the possibility that nifedipine may have the same side effect on systemic arteries if CaSR is upregulated in the vascular smooth muscle of the small and resistance arteries in patients with systemic hypertension.

The data from this study show that the dihydropyridine Ca2+ channel blockers (e.g., nifedipine and nicardipine) not only block VDCC (which would decrease [Ca2+]cyt), but also activate CaSR (which would increase [Ca2+]cyt) in PASMC. Importantly, the dose or concentration range at which dihydropyridines block VDCC (100 nM to 1 µM) in vascular smooth muscle cells50, 51 overlaps with the dose range at which dihydropyridines activate CaSR (EC50 = 0.20 µM for nifedipine). It is thus impossible to differentiate these two opposite effects of nifedipine (and other dihydropyridine Ca2+ channel blockers) using different concentrations or doses. These observations imply that, in IPAH patients (e.g., vasoreactive responders) with downregulated voltage-gated K+ (Kv) channels in PASMC52–54 where membrane potential is depolarized and VDCC is opened, the dihydropyridine Ca2+ channel blockers (e.g., nifedipine and nicardipine) should be a good therapeutic approach.4 In IPAH patients with upregulated CaSR (and/or upregulated TRPC channels) in PASMC14, 20, however, the therapeutic effect of nifedipine and nicardipine (by blocking VDCC) is potentially compromised by the stimulatory effect on CaSR. Our in vivo experiments from this study show that intraperitoneal injection of nifedipine in rats with established MCT-PH actually exacerbated the pulmonary vascular hemodynamics or further enhanced pulmonary arterial pressure (determined by RVSP via right heart catheterization) and right ventricular hypertrophy (determined by the Fulton index). For IPAH patients with upregulated CaSR in PASMC or with the “gain-of-function” mutations in the CASR gene, it may be more appropriate to use non-dihydropyridine Ca2+ channel blockers (e.g., diltiazem and verapamil) in combination with CaSR antagonists or calcilytics (e.g., NPS-2143) and/or TRPC channel blockers in order to prevent the further activation of CaSR and progression of the disease.

The stimulatory effect of dihydropyridines on CaSR or CaSR-mediated increase in [Ca2+]cyt in PASMC is not correlated to their inhibitory or augmenting effect on VDCC. Both dihydropyridine blockers (nifedipine and nicardipine) and activators (Bay K8644) activate CaSR and enhance CaSR-mediated increases in [Ca2+]cyt in IPAH-PASMC where CaSR is upregulated. These results indicate that a) the dihydropyridine derivative-mediated activation of CaSR is unrelated to the blocking action of VDCC, and b) the specific dihydropyridine structure is somehow related to the activation of CaSR or the enhancement of CaSR-mediated increases in [Ca2+]cyt in PASMC. It is possible that CaSR and VDCC are co-localized and the binding of dihydropyridine blockers to VDCC also activates the adjacent CaSR. In IPAH-PASMC, the enhanced Ca2+ influx via nifedipine-mediated activation of CaSR and subsequent activation of receptor-operated (ROC) and store-operated (SOC) Ca2+ channels outweighs the inhibitory effect of nifedipine on L-type VDCC due to upregulated CaSR, with a net effect to promote increased [Ca2+]cyt via Ca2+ influx through ROC and SOC.

In cancer cells, nifedipine and extracellular Ca2+ synergistically activate CaSR and increase [Ca2+]cyt. The resultant downregulation of the expression of thymidylate synthase and survivin promotes the sensitivity of human colon carcinoma cells and breast cancer cells to fluorouracil, a pyridine analogue, and paclitaxel, a mitotic inhibitor.55, 56 Survivin, an antiapoptotic protein that is highly expressed in cancer cells, is also expressed in PASMC from patients with IPAH and rats with MCT-induced pulmonary hypertension, but not in PASMC from normal subjects and control rats.57, 58 In vivo inhibition of survivin by inhalation of an adenovirus carrying a phosphorylation-deficient survivin mutant reverses established MCT-induced pulmonary hypertension, while in vitro inhibition of survivin by adenoviral infection of the phosphorylation-deficient survivin mutant reduces PASMC proliferation and increases apoptosis.58 It would be interesting to investigate whether nifedipine-mediated activation of CaSR downregulates survivin in PASMC, especially in PASMC from patients with IPAH and animals with experimental pulmonary hypertension, to promote PASMC apoptosis and regress established pulmonary hypertension.

In summary, the dihydropyridine Ca2+ channel blockers (nifedipine and nicardipine) block VDCC and activate CaSR. In normal PASMC where CaSR expression level is low, the predominant effect of nifedipine is to block VDCC, reduce [Ca2+]cyt and cause pulmonary vasodilation (and regression of pulmonary vascular remodeling). In PASMC isolated from patients with IPAH and animals with experimental pulmonary hypertension where CaSR is significantly upregulated, nifedipine activates CaSR and raises the resting [Ca2+]cyt. While this study has limitations due to the small number of patient samples used, the results have significant clinical relevance. The nifedipine-induced increase in the resting [Ca2+]cyt and enhancement of extracellular Ca2+-induced rise in [Ca2+]cyt would compromise its blockade effect on VDCC in IPAH-PASMC and could lead to more severe pulmonary hypertension and right ventricular hypertrophy. Therefore, the use of non-dihydropyridine Ca2+ channel blockers (e.g., diltiazem and verapamil) in combination with specific CaSR antagonists or calcilytics and/or TRPC channel blockers may be more appropriate for treatment of IPAH patients with upregulated CaSR in PASMC (or with the “gain-of-function” mutations in the CASR gene) in order to avoid the possibility of exacerbating pulmonary hypertension and right ventricular hypertrophy. Furthermore, synthesis of selective blocker of CaSR or identification of specific transcription factors that upregulate CaSR in PASMC would greatly help develop new therapeutic approach for pulmonary arterial hypertension.

Supplementary Material

1

Novelty and Significance.

What Is Known?

  • Pulmonary vascular remodeling and sustained pulmonary vasoconstriction contribute to the development of idiopathic pulmonary arterial hypertension (IPAH).

  • Increased cytosolic free Ca2+ concentration ([Ca2+]cyt) in pulmonary arterial smooth muscle cells (PASMC) triggers pulmonary vasoconstriction and stimulates PASMC proliferation leading to pulmonary vascular remodeling.

  • Dihydropyridine Ca2+ channel blockers, such as nifedipine, are used to treat patients with IPAH, however, these drugs are only effective in 15–20% of patients.

  • Ca2+-sensing receptor (CaSR) is upregulated in IPAH-PASMC, contributing to enhanced Ca2+ signaling and excessive PASMC proliferation in IPAH patients

What New Information Does This Article Contribute?

  • Dihydopyridines (e.g., nifedipine) activate CaSR resulting in an increase in [Ca2+]cyt in IPAH-PASMC, but not in normal PASMC.

  • The use of dihydropyridine Ca2+ channel blockers in IPAH patients with upregulated CaSR in PASMC might exacerbate pulmonary hypertension.

IPAH is a rare, progressive and fatal disease of unknown etiology. Sustained vasoconstriction and vascular remodeling due to PASMC proliferation are key pathogenic events that lead to early morbidity and mortality. These events have been linked to Ca2+ mobilization and signaling in PASMC, but precise therapeutic targets to interrupt these pathways have not been identified. We have previously shown that CaSR is upregulated in PASMC isolated from IPAH patients and contributes to increased [Ca2+]cyt. In this study, we demonstrate that dihydropyridine Ca2+ channel blockers, which are used to treat IPAH patients based on their ability to block voltage-dependent Ca2+ channels, activate CaSR, leading to increased [Ca2+]cyt. In contrast, non-dihydropyridine Ca2+ blockers, e.g., diltiazem and verapamil, had no effect on the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMC. Ca2+ channel blockers (i.e., nifedipine and diltiazem) have been used to effectively treat a subset of IPAH patients who are considered pulmonary vasoreactive responders. However, it is not clear why Ca2+ channel blockers are not therapeutically effective in a majority of patients with PAH, especially those with severe pulmonary hypertension. This study shows that dihydropyridine increases[Ca2+]cyt in IPAH-PASMC and that the use of dihydropyridine Ca2+ channel blockers could exacerbatepulmonaryhypertension in IPAH patients with upregulated CaSR in PASMC.

Acknowledgments

SOURCES OF FUNDING

This work was supported, in part, by grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health (HL066012, HL115014 and HL098053).

Non-standard Abbreviations

[Ca2+]cyt

Cytosolic Ca2+ concentration

PASMC

Pulmonary arterial smooth muscle cell

IPAH

Idiopathic pulmonary arterial hypertension

CaSR

Ca2+-sensing receptor

VDCC

Voltage-dependent Ca2+ channel

ROC

Receptor-operated Ca2+ channel

SOC

Store-operated Ca2+ channel

DAG

Diacyglycerol

ROCE

Receptor-operated Ca2+ entry

IP3

Inositol 1,4,5-trisphosphate

SR

Sarcoplasmic reticulum

SOCE

Store-operated Ca2+ entry

GPCR

G protein-coupled receptor

CTEPH

Chronic thromboembolic pulmonary hypertension

MCT

Monocrotaline

HPH

Hypoxia-induced pulmonary hypertension

RVSP

Right ventricular systolic pressure

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DISCLOSURES

None.

REFERENCES

  • 1.Fryer RM, Segreti JA, Widomski DL, Franklin PH, Banfor PN, Koch KA, Nakane M, Wu-Wong JR, Cox BF, Reinhart GA. Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet. J Pharmacol Exp Ther. 2007;323:217–226. doi: 10.1124/jpet.107.123901. [DOI] [PubMed] [Google Scholar]
  • 2.Smajilovic S, Yano S, Jabbari R, Tfelt-Hansen J. The calcium-sensing receptor and calcimimetics in blood pressure modulation. Br J Pharmacol. 2011;164:884–893. doi: 10.1111/j.1476-5381.2011.01317.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76:135–141. doi: 10.1161/01.cir.76.1.135. [DOI] [PubMed] [Google Scholar]
  • 4.Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
  • 5.Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest. 2001;119:128–136. doi: 10.1378/chest.119.1.128. [DOI] [PubMed] [Google Scholar]
  • 6.Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol. 2005;43:143–147. doi: 10.1016/j.vph.2005.05.004. [DOI] [PubMed] [Google Scholar]
  • 7.Douwes JM, van Loon RL, Hoendermis ES, Vonk-Noordegraaf A, Roofthooft MT, Talsma MD, Hillege HL, Berger RM. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011;32:3137–3146. doi: 10.1093/eurheartj/ehr282. [DOI] [PubMed] [Google Scholar]
  • 8.Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111. doi: 10.1161/CIRCULATIONAHA.104.488486. [DOI] [PubMed] [Google Scholar]
  • 9.Sitbon O, Humbert M, Jagot J, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998;12:265–270. doi: 10.1183/09031936.98.12020265. [DOI] [PubMed] [Google Scholar]
  • 10.Brown EM, Butters R, Katz C, Kifor O. Neomycin mimics the effects of high extracellular calcium concentrations on parathyroid function in dispersed bovine parathyroid cells. Endocrinology. 1991;128:3047–3054. doi: 10.1210/endo-128-6-3047. [DOI] [PubMed] [Google Scholar]
  • 11.Conigrave AD, Quinn SJ, Brown EM. L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci U S A. 2000;97:4814–4819. doi: 10.1073/pnas.97.9.4814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000;105:1595–1604. doi: 10.1172/JCI9038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hu J, McLarnon SJ, Mora S, Jiang J, Thomas C, Jacobson KA, Spiegel AM. A region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ J Biol Chem. 2005;280:5113–5120. doi: 10.1074/jbc.M413403200. [DOI] [PubMed] [Google Scholar]
  • 14.Yamamura A, Guo Q, Yamamura H, Zimnicka AM, Pohl NM, Smith KA, Fernandez RA, Zeifman A, Makino A, Dong H, Yuan JX-J. Enhanced Ca2+-Sensing Receptor Function in Idiopathic Pulmonary Arterial Hypertension. Circ Res. 2012;111:469–481. doi: 10.1161/CIRCRESAHA.112.266361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang J, Zhou J, Cai L, Lu Y, Wang T, Zhu L, Hu Q. Extracellular calcium-sensing receptor is critical in hypoxic pulmonary vasoconstriction. Antioxid Redox Signal. 2012;17:471–484. doi: 10.1089/ars.2011.4168. [DOI] [PubMed] [Google Scholar]
  • 16.Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239–297. doi: 10.1152/physrev.2001.81.1.239. [DOI] [PubMed] [Google Scholar]
  • 17.Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol. 2003;4:530–538. doi: 10.1038/nrm1154. [DOI] [PubMed] [Google Scholar]
  • 18.Magno AL, Ward BK, Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endocr Rev. 2011;32:3–30. doi: 10.1210/er.2009-0043. [DOI] [PubMed] [Google Scholar]
  • 19.Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Jr, Gaine SP, Orens JB, Rubin LJ. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998;98:1400–1406. doi: 10.1161/01.cir.98.14.1400. [DOI] [PubMed] [Google Scholar]
  • 20.Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004;101:13861–13866. doi: 10.1073/pnas.0405908101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ogawa A, Firth AL, Yao W, Madani MM, Kerr KM, Auger WR, Jamieson SW, Thistlethwaite PA, Yuan JX. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;297:L666–L676. doi: 10.1152/ajplung.90548.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yamamura A, Yamamura H, Zeifman A, Yuan JX. Activity of Ca2+ -activated Cl− channels contributes to regulating receptor- and store-operated Ca2+ entry in human pulmonary artery smooth muscle cells. Pulm Circ. 2011;1:269–279. doi: 10.4103/2045-8932.83447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Platoshyn O, Brevnova EE, Burg ED, Yu Y, Remillard CV, Yuan JX. Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol. 2006;290:C907–C916. doi: 10.1152/ajpcell.00028.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L, Wang JY, Rubin LJ, Yuan JX. Chronic hypoxia decreases Kv channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol. 2001;280:L801–L812. doi: 10.1152/ajplung.2001.280.4.L801. [DOI] [PubMed] [Google Scholar]
  • 25.Platoshyn O, Yu Y, Ko EA, Remillard CV, Yuan JX. Heterogeneity of hypoxia-mediated decrease in IKv and increase in [Ca2+]cyt in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L402–L416. doi: 10.1152/ajplung.00391.2006. [DOI] [PubMed] [Google Scholar]
  • 26.Firth AL, Platoshyn O, Brevnova EE, Burg ED, Powell F, Haddad GH, Yuan JX. Hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells. Ann N Y Acad Sci. 2009;1177:101–111. doi: 10.1111/j.1749-6632.2009.05040.x. [DOI] [PubMed] [Google Scholar]
  • 27.McMurtry IF. Angiotensin is not required for hypoxic constriction in salt solution-perfused rat lungs. J Appl Physiol. 1984;56:375–380. doi: 10.1152/jappl.1984.56.2.375. [DOI] [PubMed] [Google Scholar]
  • 28.McMurtry IF, Rounds S, Stanbrook HS. Studies of the mechanism of hypoxic pulmonary vasoconstriction. Adv Shock Res. 1982;8:21–33. [PubMed] [Google Scholar]
  • 29.Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am Rev Respir Dis. 1984;130:81–85. doi: 10.1164/arrd.1984.130.1.81. [DOI] [PubMed] [Google Scholar]
  • 30.Lu FH, Tian Z, Zhang WH, Zhao YJ, Li HL, Ren H, Zheng HS, Liu C, Hu GX, Tian Y, Yang BF, Wang R, Xu CQ. Calcium-sensing receptors regulate cardiomyocyte Ca2+ signaling via the sarcoplasmic reticulum-mitochondrion interface during hypoxia/reoxygenation. J Biomed Sci. 2010;17:50. doi: 10.1186/1423-0127-17-50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Riccardi D, Finney BA, Wilkinson WJ, Kemp PJ. Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR. Pflugers Arch. 2009;458:1007–1022. doi: 10.1007/s00424-009-0681-z. [DOI] [PubMed] [Google Scholar]
  • 32.Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield AE. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res. 2009;81:260–268. doi: 10.1093/cvr/cvn279. [DOI] [PubMed] [Google Scholar]
  • 33.Chow JY, Estrema C, Orneles T, Dong X, Barrett KE, Dong H. Calcium-sensing receptor modulates extracellular Ca2+ entry via TRPC-encoded receptor-operated channels in human aortic smooth muscle cells. Am J Physiol Cell Physiol. 2011;301:C461–C468. doi: 10.1152/ajpcell.00389.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Li GW, Wang QS, Hao JH, Xing WJ, Guo J, Li HZ, Bai SZ, Li HX, Zhang WH, Yang BF, Yang GD, Wu LY, Wang R, Xu CQ. The functional expression of extracellular calcium-sensing receptor in rat pulmonary artery smooth muscle cells. J Biomed Sci. 2011;18:16. doi: 10.1186/1423-0127-18-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007;293:F946–F955. doi: 10.1152/ajprenal.00474.2006. [DOI] [PubMed] [Google Scholar]
  • 36.Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol. 2005;288:H1756–H1762. doi: 10.1152/ajpheart.00739.2004. [DOI] [PubMed] [Google Scholar]
  • 37.Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S, Tfelt-Hansen J. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun. 2006;348:1215–1223. doi: 10.1016/j.bbrc.2006.07.192. [DOI] [PubMed] [Google Scholar]
  • 38.Wonneberger K, Scofield MA, Wangemann P. Evidence for a calcium-sensing receptor in the vascular smooth muscle cells of the spiral modiolar artery. J Membr Biol. 2000;175:203–212. doi: 10.1007/s00232001068. [DOI] [PubMed] [Google Scholar]
  • 39.Weston AH, Absi M, Ward DT, Ohanian J, Dodd RH, Dauban P, Petrel C, Ruat M, Edwards G. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231. Circ Res. 2005;97:391–398. doi: 10.1161/01.RES.0000178787.59594.a0. [DOI] [PubMed] [Google Scholar]
  • 40.Ziegelstein RC, Xiong Y, He C, Hu Q. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun. 2006;342:153–163. doi: 10.1016/j.bbrc.2006.01.135. [DOI] [PubMed] [Google Scholar]
  • 41.Li GW, Xing WJ, Bai SZ, Hao JH, Guo J, Li HZ, Li HX, Zhang WH, Yang BF, Wu LY, Wang R, Yang GD, Xu CQ. The calcium-sensing receptor mediates hypoxia-induced proliferation of rat pulmonary artery smooth muscle cells through MEK1/ERK1,2 and PI3K pathways. Basic Clin Pharmacol Toxicol. 2011;108:185–193. doi: 10.1111/j.1742-7843.2010.00639.x. [DOI] [PubMed] [Google Scholar]
  • 42.El Hiani Y, Ahidouch A, Roudbaraki M, Guenin S, Brule G, Ouadid-Ahidouch H. Calcium-sensing receptor stimulation induces nonselective cation channel activation in breast cancer cells. J Membr Biol. 2006;211:127–137. doi: 10.1007/s00232-006-0017-2. [DOI] [PubMed] [Google Scholar]
  • 43.Feng SL, Sun MR, Li TT, Yin X, Xu CQ, Sun YH. Activation of calcium-sensing receptor increases TRPC3 expression in rat cardiomyocytes. Biochem Biophys Res Commun. 2011;406:278–284. doi: 10.1016/j.bbrc.2011.02.033. [DOI] [PubMed] [Google Scholar]
  • 44.Rey O, Young SH, Papazyan R, Shapiro MS, Rozengurt E. Requirement of the TRPC1 cation channel in the generation of transient Ca2+ oscillations by the calcium-sensing receptor. J Biol Chem. 2006;281:38730–38737. doi: 10.1074/jbc.M605956200. [DOI] [PubMed] [Google Scholar]
  • 45.Sun YH, Li YQ, Feng SL, Li BX, Pan ZW, Xu CQ, Li TT, Yang BF. Calcium-sensing receptor activation contributed to apoptosis stimulates TRPC6 channel in rat neonatal ventricular myocytes. Biochem Biophys Res Commun. 2010;394:955–961. doi: 10.1016/j.bbrc.2010.03.096. [DOI] [PubMed] [Google Scholar]
  • 46.Topala CN, Schoeber JP, Searchfield LE, Riccardi D, Hoenderop JG, Bindels RJ. Activation of the Ca2+-sensing receptor stimulates the activity of the epithelial Ca2+ channel TRPV5. Cell Calcium. 2009;45:331–339. doi: 10.1016/j.ceca.2008.12.003. [DOI] [PubMed] [Google Scholar]
  • 47.Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341:1447–1457. doi: 10.1056/NEJM199911043411907. [DOI] [PubMed] [Google Scholar]
  • 48.Triggle DJ. Calcium channel antagonists: clinical uses--past, present and future. Biochem Pharmacol. 2007;74:1–9. doi: 10.1016/j.bcp.2007.01.016. [DOI] [PubMed] [Google Scholar]
  • 49.Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30:1103–1110. doi: 10.1183/09031936.00042107. [DOI] [PubMed] [Google Scholar]
  • 50.Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57:411–425. doi: 10.1124/pr.57.4.5. [DOI] [PubMed] [Google Scholar]
  • 51.Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, Harada K, Miyamoto S, Nakazawa H, Won KJ, Sato K. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev. 1997;49:157–230. [PubMed] [Google Scholar]
  • 52.Archer SL, London B, Hampl V, Wu X, Nsair A, Puttagunta L, Hashimoto K, Waite RE, Michelakis ED. Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. FASEB J. 2001 doi: 10.1096/fj.00-0649fje. [DOI] [PubMed] [Google Scholar]
  • 53.Archer SL, Wu X-C, Thébaud B, Nsair A, Bonnet S, Tyrrell B, McMurtry MS, Hashimoto K, Harry G, Michelakis ED. Preferential Expression and Function of Voltage-Gated, O2-Sensitive K+ Channels in Resistance Pulmonary Arteries Explains Regional Heterogeneity in Hypoxic Pulmonary Vasoconstriction. Circ Res. 2004;95:308–318. doi: 10.1161/01.RES.0000137173.42723.fb. [DOI] [PubMed] [Google Scholar]
  • 54.Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet. 1998;351:726–727. doi: 10.1016/S0140-6736(05)78495-6. [DOI] [PubMed] [Google Scholar]
  • 55.Liu G, Hu X, Chakrabarty S. Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells. Cell Calcium. 2009;45:216–225. doi: 10.1016/j.ceca.2008.10.004. [DOI] [PubMed] [Google Scholar]
  • 56.Liu G, Hu X, Premkumar L, Chakrabarty S. Nifedipine synergizes with calcium in activating the calcium sensing receptor, suppressing the expression of thymidylate synthase and survivin and promoting sensitivity to fluorouracil in human colon carcinoma cells. Mol Carcinog. 2011;50:922–930. doi: 10.1002/mc.20752. [DOI] [PubMed] [Google Scholar]
  • 57.Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol. 2006;21:385–392. doi: 10.1097/01.hco.0000231410.07426.9b. [DOI] [PubMed] [Google Scholar]
  • 58.McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479–1491. doi: 10.1172/JCI23203. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES